您好,欢迎来到半岛电竞官方网址 ! [ 登录] [ 免费注册]
半岛电竞官方网址
位置: 首页> 半岛bd体育手机客户端 库> GSK1904529A
立即咨询
咨询类型:
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
GSK1904529A
本半岛bd体育手机客户端 不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
GSK1904529A图片
CAS NO: 1089283-49-7
包装与价格:
包装 价格(元)
10 mM * 1 mL in DMSO 电议
10mg 电议
50mg 电议
100mg 电议
200mg 电议
500mg 电议

半岛bd体育手机客户端 介绍
GSK1904529A 是一种有效的,选择性的,具有口服活性和 ATP 竞争性的胰岛素样生长因子 1 受体 ( IGF-1R) 和胰岛素受体 ( IR) 抑制剂, IC50值分别为 27 和 25 nM。GSK1904529A 在其他 45 种丝氨酸/苏氨酸和酪氨酸激酶中显示出较弱的活性 ( IC50>1 μM)。GSK1904529A 具有抗肿瘤活性。
生物活性

GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor ofinsulin-like growth factor-1 receptor (IGF-1R)andinsulin receptor(IR), withIC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity[1][2].

IC50& Target

IC50: 27 nM (IGF-1R), 25 nM (IR)[1]

体外研究
(In Vitro)

GSK1904529A displays high affinities for IGF-1R and IR, with Kis of 1.6 and 1.3 nM, respectively[1].
GSK1904529A (72 h) inhibits tumor cells proliferation with IC50s ranges from 35 nM to >30 μM, and Ewing's sarcoma and multiple myeloma cell lines are greatest sensitive[1].
GSK1904529A (0.03-3 μM; 24 and 48 h) arrests cells at the G1 phase of the cell cycle[1].
GSK1904529A (2 h) inhibits phosphorylation of IGF-IR and IR with IC50s of 22 and 19 nM in NIH-3T3/LISN and NIH-3T3-hIR cells, respectively[1].
GSK1904529A (0.01-3 μM; 4 h) blocks the major downstream signal transduction pathways mediated by IGF-IR and IR in NIH-3T3/LISN and NIH-3T3-hIR cells[1].

Cell Cycle Analysis[1]

Cell Line: COLO 205, MCF-7, and NCI-H929 cells
Concentration: 0, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time: 24 and 48 hours
Result: Increased the accumulation in G1 and decreased accumulation in S and G2-M phases of the cell cycle.

Western Blot Analysis[1]

Cell Line: NIH-3T3/LISN and NIH-3T3-hIR cells
Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time: 4 hours
Result: Inhibited the ligand-induced phosphorylation of IGF-IR and IR at concentrations >0.01 μM.
Decreased the phosphorylation of AKT, IRS-1, and ERK.
体内研究
(In Vivo)

GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has antitumor activity in mice[1].
GSK1904529A (1-30 mg/kg; a single p.o.) decreases IGF-I-induced IGF-IR phosphorylation in a dose-dependent manner in mice[1].
GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has no significant alterations in the blood glucose levels in mice[1].

Animal Model: Female athymicnu/nuCD-1 mice are bring NIH-3T3/LISN tumor[1]
Dosage: 30 mg/kg
Administration: P.o. once or twice daily for 21 d
Result: Resulted in 56% (once daily) and 98% (twice daily) inhibition of tumor growth.
No significant decrease in body weight on the once-daily schedule.
Observed 11-13% of body weight loss, and recovered to near baseline 6 days after the cessation of treatment in twice-daily group.
分子量

851.96

性状

Solid

Formula

C44H47F2N9O5S

CAS 号

1089283-49-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro:

DMSO : 50 mg/mL(58.69 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量 1 mg 5 mg 10 mg
1 mM 1.1738 mL 5.8688 mL 11.7376 mL
5 mM 0.2348 mL 1.1738 mL 2.3475 mL
10 mM 0.1174 mL 0.5869 mL 1.1738 mL
*

请根据半岛bd体育手机客户端 在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端 失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO40%PEG3005%Tween-8045% saline

    Solubility: ≥ 2.75 mg/mL (3.23 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (3.23 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
* 以上所有助溶剂都可在本网站选购。
Baidu
map